Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes

Sponsor
Kissei Pharmaceutical Co., Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT00721656
Collaborator
(none)
80
5
2
16

Study Details

Study Description

Brief Summary

To evaluate the efficacy and safety of KLS-0611 compared to placebo in patients with dry eye syndromes.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo

Drug: Placebo

Experimental: KLS-0611

Drug: KLS-0611

Outcome Measures

Primary Outcome Measures

  1. Corneal-conjunctival staining [4 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Corneal and conjunctival damage

  • Insufficiency of lacrimal secretion

  • Ocular symptom

Exclusion Criteria:
  • Severe ophthalmic disorder

  • Punctual plugs or surgery for occlusion of the lacrimal puncta

Contacts and Locations

Locations

Site City State Country Postal Code
1 Japan Hokkaido region Japan
2 Japan Kansai region Japan
3 Japan Kanto region Japan
4 Japan Kyushu region Japan
5 Japan Shikoku region Japan

Sponsors and Collaborators

  • Kissei Pharmaceutical Co., Ltd.

Investigators

  • Study Director: Yasuhiro Omori, Kissei Pharmaceutical Co., Ltd.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00721656
Other Study ID Numbers:
  • KLS1201
First Posted:
Jul 24, 2008
Last Update Posted:
Mar 18, 2009
Last Verified:
Mar 1, 2009

Study Results

No Results Posted as of Mar 18, 2009